Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared the imaging features of patients with isolated cardiac FDG uptake on positron emission tomography with those who had findings indicative of systemic sarcoidosis.
|
29721764 |
2020 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This makes an intriguing case for FDG PET-CT use with pretest diet prep over cardiac MRI (CMR) for cardiac sarcoid evaluation, given that CMR is likely to overlook these extra-thoracic sites of disease.
|
28681340 |
2019 |
Sarcoidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It has correlation with a more acute and symptomatic phase of thoracic sarcoidosis and therefore expected to show a more severely increased metabolic activity on FDG PET.
|
31274614 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
F-FDG PET/CT imaging is a noninvasive imaging technique that can be crucial in the diagnosis of sarcoidosis of the spinal cord and help avoid unnecessary procedures.
|
31634300 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Between 2010 and 2018, 222 patients with chronic sarcoidosis and presence of prolonged symptoms of active disease were referred to FDG PET/CT.
|
31195715 |
2019 |
Sarcoidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It has correlation with a more acute and symptomatic phase of thoracic sarcoidosis and therefore expected to show a more severely increased metabolic activity on FDG PET.
|
31162254 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT has proven to be a reliable tool for therapy monitoring in sarcoidosis.
|
31197630 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of <sup>18</sup>F-FDG PET/CT in Suspected Intraocular Sarcoidosis and Tuberculosis.
|
31743044 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT enabled the diagnosis of presumed sarcoidosis in these six patients.
|
30658987 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG PET/CT appeared to have a higher SUVmax for the differential diagnosis of sarcoidosis and benign pulmonary lesions.
|
31367534 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The follow-up F-FDG PET/CT 4 months later showed a complete response of the sarcoidosis myositis.
|
31274562 |
2019 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
18F-FDG PET and MRI image fusion allows clinicians to obtain complete morphofunctional cartography in patients with sarcoidosis.
|
27604109 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorine-18 fluorodeoxygluose (<sup>18</sup>F-FDG) positron emission tomography (PET) is a useful tool for evaluating disease activity in sarcoidosis including cardiac involvement.
|
29681578 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a rare case of a 37-year-old woman with bihilar, mediastinal, and abdominal lymphadenopathy in conjunction with a histologically proven cutaneous manifestation of sarcoidosis in a tattoo of the lower back exhibiting an increased uptake of FDG.
|
29538031 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroid gland characteristics of patients with a clinical diagnosis of NF1 who underwent <sup>18</sup>F-FDG PET/CT imaging for the first time to distinguish benign neurofibroma from malignant peripheral nerve sheath tumor (MPNST) at our institution (<i>n</i> = 69) were compared to PET/CT imaging of sarcoidosis (<i>n</i> = 25) and early stage lung cancer (T<sub>1</sub>N<sub>0</sub>M<sub>0</sub> tumors, <i>n</i> = 15) patients.
|
30023349 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate the clinical utility of <sup>18</sup>F-FDG PET/CT for therapeutic evaluation and prognostic prediction in sarcoidosis.
|
29686996 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 75-year-old woman with a history of sarcoidosis presenting with low cardiac output and complete right bundle-branch block underwent 4'-[methyl-C]-thiothymidine (4DST) PET/CT after cardiac MRI and FDG PET/CT for the evaluation of suspected cardiac sarcoidosis (CS) before treatment.
|
29538030 |
2018 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monitoring the Therapy of Extensive Osseous Sarcoidosis With FDG PET/CT.
|
28240658 |
2017 |
Sarcoidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET has been used in sarcoidosis for diagnosis and determination of the extent of the disease.
|
28853043 |
2017 |